ENTRANCE POLICY: Professional Beauty is reserved for trade and professional visitors only. Due to the professional nature of the event, babies and children under 16 cannot be admitted.
Allergan acquires Elastagen to enhance injectables portfolio 12 February 2018     Global pharmaceutical company Allergan, which manufactures Botox as well as dermal fillers, has acquired Sydney-based company, Elastagen, whose technology is based on tropoelastin, the precursor of elastin – a key component of youthful skin. Tropoelastin is described as a ‘youth protein’. According to Elastagen, its version of tropoelastin is identical to that present in human tissue, and has many potential clinical applications, including treatment for acne scars, stretch marks, aesthetic skin repair and surgical wound repair. Says Bill Meury, chief commercial officer at Dublin-headquartered Allergan: “This acquisition and the development of a next generation of injectables based on this technology will ensure Allergan offers innovative filler products for years to come.” Robert Daniels, Elastagen CEO, added: “Partnering with Allergan, a leader in medical aesthetics, is incredibly exciting. I thank the Elastagen team for their hard work and dedication in developing our innovative tropoelastin product pipeline and look forward to working with Allergan to take these products to market.”
Cape Town 4 - 5 March 2018 Durban 20 May 2018 Johannesburg 2 - 3 September 2018 Education - Innovation - Inspiration